Latest News about AZN
Recent news which mentions AZN
2 Steady Stocks to Buy and Hold Forever
March 17, 2023
From Motley Fool
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
From Benzinga
From Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
March 09, 2023
From Benzinga
3 No-Brainer Stocks to Buy With $400 Right Now
March 08, 2023
From Motley Fool
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
From Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
March 06, 2023
From InvestorPlace
AstraZeneca says cancer drug Enhertu showed positive results
March 06, 2023
Tickers
AZN
From MarketWatch
From Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
February 28, 2023
From Motley Fool
Why Compugen Shares Are Up Today
February 28, 2023
From Motley Fool
This chart gives one reason European stocks may continue to outperform U.S. equities
February 17, 2023
From MarketWatch
The hunt for stocks with rising dividends: These fund managers have a strategy to keep your payouts growing
February 13, 2023
From MarketWatch
AstraZeneca Plc (AZN) Q4 2022 Earnings Call Transcript
February 09, 2023
Tickers
AZN
From Motley Fool
Tickers
AZN
From MarketWatch
2 Top Biotech Stocks to Buy Right Now
February 09, 2023
From Motley Fool
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
February 09, 2023
From Benzinga
US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst
February 09, 2023
From Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
February 08, 2023
From Motley Fool
AstraZeneca says Forxiga approved in EU for heart failure
February 07, 2023
Tickers
AZN
From MarketWatch
Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report
February 06, 2023
From Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
From Motley Fool
Top 5 Health Care Stocks That May Rally
February 03, 2023
From Benzinga
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
February 02, 2023
From Benzinga
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
February 01, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.